...
机译:P2.01-48 NSCLC患者IIIB患者的预测因子/ IV患者用第一线铂 - 双峰化疗治疗
Division of Oncology and Pathology Department of Clinical Sciences Lund Lund University;
Division of Oncology and Pathology Department of Clinical Sciences Lund Lund University;
Division of Oncology and Pathology Department of Clinical Sciences Lund Lund University;
Department of Respiratory Medicine Skane University Hospital;
Department of Radiotherapy Skane University Hospital;
Division of Oncology and Pathology Department of Clinical Sciences Lund Lund University;
Division of Oncology and Pathology Department of Clinical Sciences Lund Lund University;
Division of Oncology and Pathology Department of Clinical Sciences Lund Lund University;
机译:P2.01-48 NSCLC患者IIIB患者的预测因子/ IV患者用第一线铂 - 双峰化疗治疗
机译:化疗治疗的IV期非小细胞肺癌(NSCLC)患者的治疗前临床预后因素
机译:一线诱导化疗后表现良好状态仍未进展的IIIb / IV期非小细胞肺癌(NSCLC)患者维持治疗的贝叶斯网络荟萃比较:按表现状态,EGFR突变,组织学和对既往反应的结果感应
机译:细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
机译:晚期(IIIB和IV)非小细胞肺癌患者症状管理的评估
机译:一线治疗IIIB–IV期非小细胞肺癌(NSCLC)患者的三联与双联有或没有顺铂:一项多中心随机因子试验(FAST)
机译:PCN97先进的非小细胞肺癌(NSCLC)西妥昔单抗治疗决策模型:化学疗法+西妥昔单抗VS。切图昔单抗治疗策略化疗仅用于IIIB / IV期NSCLC的一线治疗